Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Safety and Tolerability - Incidence of treatment emergent adverse events as assessed by type and severity |
The incidence, type and severity of treatment emergent adverse events |
From time 0 to 51 days after first dosing (29 days after fourth dosing) ] |
|
Secondary |
Pharmacokinetics - Area under the plasma concentration-time curve - through |
AUCt, Area under the plasma concentration-time curve from zero to through concentration. |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|
Secondary |
Pharmacokinetics - Area under the plasma concentration-time curve - infinity |
AUCinf, Area under the plasma concentration-time curve from zero to infinity concentration. |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|
Secondary |
Pharmacokinetics - Area under the plasma concentration-time curve - last |
AUClast, Area under the plasma concentration-time curve-from zero to last concentration. |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|
Secondary |
Pharmacokinetics - Maximum plasma concentration - Cmax |
Cmax, Measured maximum plasma drug concentration after dosing |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|
Secondary |
Pharmacokinetics - Time to maximum plasma concentration - Tmax |
Tmax, Sampling time until reaching Cmax after dosing |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|
Secondary |
Pharmacokinetics - Elimination rate constant - ?z |
?z, Elimination rate constant |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|
Secondary |
Pharmacokinetics - Half-life - t½ |
t½, Half-life of ZP7570 |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|
Secondary |
Pharmacokinetics - Volume of distribution - Vz/f |
Vz/f, Apparent volume of distribution of ZP7570 during terminal phase |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|
Secondary |
Pharmacokinetics - Body clearance - CL/f |
CL/f, Apparent total body clearance |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|
Secondary |
Pharmacokinetics - Mean residence time - MRT |
MRT, Mean residence time |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|
Secondary |
Pharmacodynamics - Acetaminophen concentration-time curves |
Acetaminophen concentration-time curves following ingestion of mixed meal test and acetaminophen |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose |
|
Secondary |
Pharmacodynamics - Maximum acetaminophen concentration - Cmax |
Cmax, maximum acetaminophen concentration following ingestion of mixed meal test and acetaminophen |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose |
|
Secondary |
Pharmacodynamics - Time to maximum acetaminophen concentration - Tmax |
Tmax, Time to maximum acetaminophen concentration following ingestion of mixed meal test and acetaminophene |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Area under the concentration-time curve - AUCacetaminohen,0-60min |
AUCacetaminohen,0-60min, area under the acetaminophen concentration-time curve from 0 to 60 min post-ingestion |
From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose |
|
Secondary |
Pharmacodynamics - Area under the concentration-time curve - AUCacetaminohen,0-240min |
AUCacetaminohen,0-240min, area under the acetaminophen concentration -time curve from 0 to 240 min post-ingestion |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Plasma glucose concentration-time curves |
Plasma glucose concentration-time curves following ingestion of mixed meal test and acetaminophen |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose |
|
Secondary |
Pharmacodynamics - Maximum plasma glucose concentration - Cmax |
Cmax, Maximum plasma glucose concentration following ingestion of mixed meal test and acetaminophen |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose |
|
Secondary |
Pharmacodynamics - Time to maximum plasma glucose concentration - Tmax |
Tmax, Time to maximum plasma glucose concentration following ingestion of mixed meal test and acetaminophen |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Area under the concentration-time curve - AUCplasma glucose,0-60min |
AUCplasma glucose,0-60min, area under the plasma glucose concentration-time curve from 0 to 60 min post-ingestion |
From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Area under the concentration-time curve - AUCplasma glucose,0-240min |
AUCplasma glucose,0-240min, area under the acetaminophen concentration -time curve from 0 to 240 min post-ingestion |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Insulin concentration-time curves |
Insulin concentration-time curves following ingestion of mixed meal test and acetaminophen |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Maximum insulin concentration - Cmax |
Cmax, Maximum insulin concentration following ingestion of mixed meal test and acetaminophen |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Time to maximum insulin concentration - Tmax |
Tmax, Time to maximum insulin concentration following ingestion of mixed meal test and acetaminophen |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Area under the concentration-time curve - AUCinsulin,0-60min |
AUCinsulin,0-60min, area under the insulin concentration-time curve from 0 to 60 min post-ingestion |
From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Area under the concentration-time curve - AUCinsulin, 0-240min |
AUCinsulin,0-240min, area under the insulin concentration-time curve from 0 to 240 min post-ingestion |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Glucagon concentration-time curves (optional) |
Glucagon concentration-time curves following ingestion of mixed meal test and acetaminophen |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Maximum glucagon concentration - Cmax (optional) |
Cmax, Maximum glucagon concentration following ingestion of mixed meal test and acetaminophen |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Time to maximum glucagon concentration - Tmax (optional) |
Tmax, Time to maximum glucagon concentration following ingestion of mixed meal test and acetaminophen |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Area under the concentration-time curve - AUCglucagon,0-60min (optional) |
AUCglucagon,0-60min, area under the glucagon concentration-time curve from 0 to 60 min post-ingestion |
From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Area under the concentration-time curve - AUCglucagon, 0-240min (optional) |
AUCglucagon,0-240min, area under the glucagon concentration-time curve from 0 to 240 min post-ingestion |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Free fatty acids concentration-time curves |
Free fatty acids concentration-time curves following ingestion of mixed meal test and acetaminophen |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Maximum free fatty acids concentration - Cmax |
Cmax, Maximum free fatty acids concentration following ingestion of mixed meal test and acetaminophen |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Time to maximum free fatty acids concentration - Tmax |
Tmax, Time to maximum free fatty acids concentration following ingestion of mixed meal test and acetaminophen |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Area under the concentration-time curve - AUCfree fatty acids, 0-60min |
AUCfree fatty acids,0-60min, area under the free fatty acids concentration-time curve |
From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Area under the concentration-time curve - AUCfree fatty acids, 0-240min |
AUCfree fatty acids,0-240min, area under the free fatty acids concentration-time curve |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Triglycerides concentration-time curves |
Triglycerides concentration-time curves following ingestion of mixed meal test and acetaminophen |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Maximum triglycerides concentration - Cmax |
Cmax, Maximum triglycerides concentration following ingestion of mixed meal test and acetaminophen |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Time to maximum triglycerides concentration - Tmax |
Tmax, Time to maximum triglycerides concentration following ingestion of mixed meal test and acetaminophen |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Area under the concentration-time curve - AUCtriglycerides, 0-60min |
AUCtriglycerides,0-60min, area under the triglycerides concentration-time |
From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Pharmacodynamics - Area under the concentration-time curve - AUCtriglycerides,0-240min |
AUCtriglycerides,0-240min, area under the triglycerides concentration-time curve |
From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose |
|
Secondary |
Anti-ZP7570 antibodies - Incidence and titres |
Overall anti-ZP7570 antibody incidence and titers. Incidence of anti-ZP7570 antibodies cross-reacting with endogenous GLP-1 or GLP-2. |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|
Secondary |
Safety Lab - Haematological values vs. reference ranges and baseline |
Abnormal values or changes in haematology. |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|
Secondary |
Safety Lab - Clinical chemistry values vs. reference ranges and baseline |
Abnormal values or changes in chemical chemistry |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|
Secondary |
Safety Lab - Urinalysis values vs. reference ranges and baseline |
Abnormal values or changes in urinalysis |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|
Secondary |
Safety - Vital signs: blood pressure |
Changes in diastolic and systolic blood pressure (in mmHg) |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|
Secondary |
Safety - Vital signs: pulse |
Changes in pulse (beats per minute) |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|
Secondary |
Safety - Physical Examination |
Changes in physical examination of the body. Outcome will be measured as 'normal' or 'abnormal', if abnormal as 'not clinically significant' or 'clinically significant'. |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|
Secondary |
Safety - ECG |
Changes or abnormalities in ECG parameters (in ms): Heart rate, PR, QRS, QT, QTcF |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|
Secondary |
Safety - Injection site reactions |
Occurrence of injection site reactions |
From time 0 to 51 days after first dosing (29 days after fourth dosing) |
|